Expanding Alhemo to hemophilia without inhibitors recommended
A committee of the European Medicines Agency (EMA) has recommended that the approval of Alhemo (concizumab-mtci) be expanded to…
Articles by Marisa Wexler, MS
Hympavzi lowers bleeding rates for hemophilia patients with inhibitors
Preventive treatment with Hympavzi (marstacimab-hncq) can effectively reduce bleeding rates in people with hemophilia A or B…
CAR T-cell therapy successfully treats man’s acquired hemophilia A
CAR T-cell therapy, a type of treatment that weaponizes the body’s immune system and was originally developed to treat cancer,…
Jivi approved by FDA for children with hemophilia A as young as 7
Jivi (damoctocog alfa pegol) has received approval from the U.S. Food and Drug Administration (FDA) that now extends to children…
Gene therapy BBM-H901 approved for hemophilia B in China
The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia B,…
Altuviiio approved to treat hemophilia A in Canada
Health Canada has approved Altuviiio (efanesoctocog alfa) to treat children, adolescents, and adults with hemophilia A, with the…
Pfizer discontinues hemophilia B treatment Beqvez
Pfizer said it will stop development and commercialization of hemophilia B treatment Beqvez (fidanacogene elaparvovec-dzkt). “Pfizer has made…
California center is first in state to offer Hympavzi for hemophilia B
The Loma Linda University Health (LLUH) Hemophilia Treatment Center has become the first clinic in California offering Hympavzi (marstacimab)…
Ixinity safe, effective in young children with hemophilia B: Trial
Ixinity (trenonacog alfa) can effectively prevent and control bleeds in young children with severe or moderately severe hemophilia…
After 4 years, hemophilia B bleeding rates remain low with Hemgenix
Four years after treatment with the gene therapy Hemgenix (etranacogene dezaparvovec), most people with hemophilia B aren’t taking…